113452
Dear Sir/Madam, Thank you for your quick reply and clarification. I would like to ask for other techical information: 1. What is the usefull concentration range of purified HMT enzyme (H3-K4 specific) for this kit (ab113452)? 2. Can I use the product ab80377 "SMYD3 protein (Active)" as purified recombinant protein in this kit? Thank you Your Sincerely
113452
Dear Sir/Madam,I would like to have some techical information about your product ab113452 EpiSeeker Histone Methyltransferase H3(K4) Activity Quantification Assay Kit.- Can I use a purified HMT enzyme rather than nuclear extract to carry out my assay?- If not. Can you suggest an other colorimetric assay that allows to do
Thank you for your enquiry regarding ab113452. 1. The biotinylated substrate is unmethylated histone peptide and used for H3-K9 specific histone methyltransferase reaction. 2. For generating a standard curve, first, dilute HK5 HMT Standard with HK2 Assay Buffer to 5 ng/µl by adding 5 µl of HK5 to 5 µl of HK2. Then, further prepare five concentrations by combining the 5 ng/µl Diluted HK5 with HK2 into final concentrations of 0.2, 0.5, 1.0, 2.0, and 5.0 ng/µl according to the following dilution chart. Then add 2 ul of diluted HK5 at different concentrations to each assay well. Tube HK5(5 ng/µl) HK2 Resulting HK5 Concentration 1 0.5 µl 24.5 µl 0.1 ng/µ 2 1.0 µl 24.0 µl 0.2 ng/µl 3 1.0 µl 9.0 µl 0.5 ng/µl 4 1.0 µl 4.0 µl 1.0 ng/µl 5 2.0 µl 3.0 µl 2.0 ng/µl 6 4.0 µl 0.0 µl 5.0 ng/µl I hope this will be useful for you.
This research was supported in part by grants from the National Institutes of Health (CA143971, DK055748, RR024975, CA113452), by a Merit Review Award from the Veterans Administration and by a Postdoctoral Fellowship Award to David DeGraff from the American Cancer Society Great Lakes Division.
This research was supported by National Institutes of Health grants P01HL076491, P01HL103453, P01HL098055, R01HL103866, R01HL103931, and P20HL113452 and by the Cleveland Clinic Clinical Research Unit of the Case Western Reserve University CTSA (UL1TR 000439-06).
This research was supported by National Institutes of Health (NIH) grants P01HL076491, 1P01HL098055, and 5P01HL103453 and the Leducq Fondation. The GeneBank study has been supported by NIH grants R01HL103866, 1P20HL113452, 1R01HL103931, and R01ES021801 and the Cleveland Clinic Clinical Research Unit of the Case Western Reserve University CTSA (UL1TR 000439-06). 041b061a72